Semaglutide ya jawo hankali sosai don tasirin sa a cikin sarrafa nauyi

A matsayin GLP-1 agonist, yana kwaikwayi tasirin physiological na GLP-1 da aka saki ta halitta a cikin jiki.

Dangane da cin abinci na glucose, PPG neurons a cikin tsarin kulawa na tsakiya (CNS) da L-cell a cikin gut suna samar da su kuma suna ɓoye GLP-1, hormone na gastrointestinal inhibitory.

Bayan an sake shi, GLP-1 yana kunna masu karɓar GLP-1R akan ƙwayoyin β-pancreatic, yana haifar da jerin canje-canje na rayuwa wanda ke da alaƙa da ɓoyewar insulin da kuma hana ci.

Fitar da insulin yana haifar da raguwar matakan glucose na jini gaba ɗaya, raguwar samar da glucagon, da rigakafin sakin glucose daga shagunan glycogen na hanta. Wannan yana haifar da satiety, yana inganta haɓakar insulin, kuma a ƙarshe yana haifar da asarar nauyi.

Magungunan yana haɓaka haɓakar insulin ta hanyar dogaro da glucose, don haka yana rage haɗarin hypoglycemia. Bugu da ƙari, yana da tasiri mai kyau na dogon lokaci akan rayuwa, haɓakawa, da sake farfadowa na β-cell.

Bincike ya nuna cewa semaglutide da farko yana kwaikwayon tasirin GLP-1 da aka saki daga hanji maimakon daga kwakwalwa. Wannan saboda yawancin masu karɓar GLP-1 a cikin kwakwalwa suna kwance a waje da ingantaccen kewayon waɗannan magungunan da ake sarrafa su ta tsarin. Duk da iyakancewar aikinsa kai tsaye akan masu karɓar GLP-1 na kwakwalwa, semaglutide ya kasance mai tasiri sosai wajen rage yawan abinci da nauyin jiki.

Ya bayyana don cimma wannan ta hanyar kunna hanyoyin sadarwar neuronal a cikin tsarin kulawa na tsakiya, yawancin su makasudin sakandare ne waɗanda ba sa bayyana masu karɓar GLP-1 kai tsaye.

A cikin 2024, samfuran kasuwanci da aka amince da su na semaglutide sun haɗa daOzempic, Rybelsus, kumaWegovyalluran da Novo Nordisk suka yi.